Shield pilots ironclad specialty future with Feraccru

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward, Informa Pharma Intelligence’s insights global director of content, his ambitions to build a West European and US-focused specialty pharma while seeking in-country specialists to partner other markets.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Carl Sterritt – CEO, Shield Therapeutics